AANP PMHNP CERTIFICATION EXAM 2026 |
COMPLETE PRACTICE QUESTIONS &
VERIFIED ANSWERS WITH DETAILED
RATIONALES | PSYCHIATRIC-MENTAL
HEALTH NURSE PRACTITIONER BOARD
EXAM STUDY GUIDE
AANP PMHNP CERTIFICATION EXAM 2026 | COMPLETE PRACTICE QUESTIONS &
VERIFIED ANSWERS WITH DETAILED RATIONALES
DOCUMENT OVERVIEW
• 200 comprehensive multiple-choice questions designed to mirror the actual
PMHNP Board Examination, covering all major clinical domains with verified correct
answers and detailed rationales for each question.
• Study this material by reviewing one section at a time, then use the rationales
to deepen your understanding of pathophysiology, pharmacology, and clinical
decision-making—focus on why answers are correct, not just memorization.
QUESTIONS BEGIN
QUESTION 1: Neurobiology & Pathophysiology
A 45-year-old male presents with persistent depressed mood, anhedonia, and
difficulty concentrating for 3 weeks. Which neurotransmitter dysfunction is
most directly implicated in the neurobiological basis of major depressive
disorder?
A) Excessive acetylcholine in the nucleus accumbens
B) Deficient serotonin, norepinephrine, and dopamine in key brain circuits
C) Elevated gamma-aminobutyric acid (GABA) in the amygdala
D) Excessive glutamate throughout the prefrontal cortex
,E) Deficient acetylcholine in the hippocampus
CORRECT ANSWER: B) Deficient serotonin, norepinephrine, and dopamine
in key brain circuits
RATIONALE: The monoamine hypothesis of depression posits that major
depressive disorder results from insufficient levels of serotonin, norepinephrine,
and dopamine in critical neural circuits including the prefrontal cortex, anterior
cingulate cortex, and striatum. This is the foundational neurobiological theory that
guided development of first-generation antidepressants (SSRIs, SNRIs, tricyclics).
While the hypothesis has evolved and is not universally sufficient to explain all
depression, it remains the primary neurochemical model taught and applied
clinically. Option A (acetylcholine) is implicated in Alzheimer's disease and attention
deficits, not primary mood disorders. Option C (elevated GABA) would suggest
anxiolytic activity, not depressive symptoms. Option D (excessive glutamate) is
associated with excitotoxicity in neurodegenerative disease and some mood
dysregulation, but elevated—not deficient—glutamate is the concern. Option E
(acetylcholine deficiency) is relevant to cognitive disorders, not depression.
QUESTION 2: Psychopharmacology - SSRIs
A 38-year-old woman with generalized anxiety disorder is prescribed
sertraline 50 mg daily. She reports nausea, restlessness, and insomnia
beginning 3 days after initiation. Which intervention is most appropriate at
this time?
A) Discontinue sertraline immediately and switch to a tricyclic antidepressant
B) Reassure the patient that these symptoms typically resolve within 1–2 weeks and
continue the current dose
C) Increase the dose to 100 mg to achieve therapeutic levels faster
D) Add benzodiazepine monotherapy and taper sertraline over 1 week
E) Switch to fluoxetine, which has fewer initial adverse effects
, CORRECT ANSWER: B) Reassure the patient that these symptoms typically
resolve within 1–2 weeks and continue the current dose
RATIONALE: Initial SSRI side effects (nausea, agitation, insomnia) are common and
predictable, occurring in 20–30% of patients in the first week. These are dose-
independent and typically resolve within 7–14 days as the brain adapts. Early
discontinuation or dose escalation often perpetuates the cycle of side effects.
Standard practice is to reassure, counsel the patient on timing expectations,
consider timing adjustment (e.g., taking sertraline in the morning to mitigate
insomnia), and allow time for tolerance. Option A (discontinuation) is premature
and abandons an evidence-based first-line agent. Option C (escalation) worsens
tolerability. Option D (benzodiazepine monotherapy) is inappropriate monotherapy
and adds dependence risk. Option E (fluoxetine switch) is unnecessary; the side-
effect profile is similar across SSRIs, and switching provides no advantage at this
stage.
QUESTION 3: Diagnostic Assessment - Bipolar I Disorder
A 29-year-old male is brought to the clinic by his wife after a 5-day period of
decreased need for sleep (3 hours/night), pressured speech, racing thoughts,
and impulsive spending of $8,000. He has no prior psychiatric history. Which
diagnosis best fits this clinical presentation?
A) Attention-deficit/hyperactivity disorder with impulsivity
B) Major depressive disorder with agitation
C) Bipolar I disorder, current manic episode
D) Substance-induced mood disorder
E) Generalized anxiety disorder with restlessness
CORRECT ANSWER: C) Bipolar I disorder, current manic episode
RATIONALE: The presentation meets DSM-5 criteria for a manic episode: a distinct
period of abnormally and persistently elevated/expansive mood lasting ≥3 days
(here, 5 days), plus ≥3 of the DIGFAST criteria (Distractibility, Impulsivity,
, Grandiosity/goal-directedness, Flight of ideas, Activity increase, Sleep decrease,
Talkativeness). This patient exhibits flight of ideas, decreased sleep need, goal-
directed activity (spending), pressured speech, and impulsivity—classic manic
features. First manic episode with no prior major depressive episodes = Bipolar I
Disorder. Option A (ADHD) does not account for the acute mood elevation and
dramatic behavioral shift. Option B (major depression with agitation) lacks
depressed mood and misinterprets the presentation. Option D (substance-induced)
requires substance use history; none is provided. Option E (GAD) does not explain
the decreased sleep need or goal-directed activity characteristic of mania.
QUESTION 4: Psychopharmacology - Mood Stabilizers
A 34-year-old female with Bipolar I Disorder has been stable on lithium 900
mg daily (level 0.8 mEq/L) for 18 months. She presents with tremor, polyuria,
and polydipsia. Which complication is most concerning in this scenario?
A) Acute lithium toxicity requiring immediate dialysis
B) Nephrogenic diabetes insipidus as a chronic lithium side effect
C) Hypothyroidism secondary to chronic lithium use
D) Nephrotic syndrome from glomerulonephritis
E) Metabolic acidosis from lithium accumulation
CORRECT ANSWER: B) Nephrogenic diabetes insipidus as a chronic lithium
side effect
RATIONALE: Polyuria and polydipsia in a patient on chronic lithium therapy
strongly suggest nephrogenic diabetes insipidus (NDI), a dose-dependent but often
irreversible side effect affecting the collecting duct's response to antidiuretic
hormone. Tremor is an expected dose-related effect of lithium. The lithium level
(0.8 mEq/L) is within the therapeutic range (0.6–1.2 mEq/L), making acute toxicity
unlikely. NDI occurs in 20–40% of patients on long-term lithium and manifests as
polyuria, polydipsia, and inability to concentrate urine. While hypothyroidism is a
common lithium side effect (occurring in ~30% of patients), it does not explain the
acute polyuria and polydipsia. Option A (acute toxicity) is inconsistent with a
COMPLETE PRACTICE QUESTIONS &
VERIFIED ANSWERS WITH DETAILED
RATIONALES | PSYCHIATRIC-MENTAL
HEALTH NURSE PRACTITIONER BOARD
EXAM STUDY GUIDE
AANP PMHNP CERTIFICATION EXAM 2026 | COMPLETE PRACTICE QUESTIONS &
VERIFIED ANSWERS WITH DETAILED RATIONALES
DOCUMENT OVERVIEW
• 200 comprehensive multiple-choice questions designed to mirror the actual
PMHNP Board Examination, covering all major clinical domains with verified correct
answers and detailed rationales for each question.
• Study this material by reviewing one section at a time, then use the rationales
to deepen your understanding of pathophysiology, pharmacology, and clinical
decision-making—focus on why answers are correct, not just memorization.
QUESTIONS BEGIN
QUESTION 1: Neurobiology & Pathophysiology
A 45-year-old male presents with persistent depressed mood, anhedonia, and
difficulty concentrating for 3 weeks. Which neurotransmitter dysfunction is
most directly implicated in the neurobiological basis of major depressive
disorder?
A) Excessive acetylcholine in the nucleus accumbens
B) Deficient serotonin, norepinephrine, and dopamine in key brain circuits
C) Elevated gamma-aminobutyric acid (GABA) in the amygdala
D) Excessive glutamate throughout the prefrontal cortex
,E) Deficient acetylcholine in the hippocampus
CORRECT ANSWER: B) Deficient serotonin, norepinephrine, and dopamine
in key brain circuits
RATIONALE: The monoamine hypothesis of depression posits that major
depressive disorder results from insufficient levels of serotonin, norepinephrine,
and dopamine in critical neural circuits including the prefrontal cortex, anterior
cingulate cortex, and striatum. This is the foundational neurobiological theory that
guided development of first-generation antidepressants (SSRIs, SNRIs, tricyclics).
While the hypothesis has evolved and is not universally sufficient to explain all
depression, it remains the primary neurochemical model taught and applied
clinically. Option A (acetylcholine) is implicated in Alzheimer's disease and attention
deficits, not primary mood disorders. Option C (elevated GABA) would suggest
anxiolytic activity, not depressive symptoms. Option D (excessive glutamate) is
associated with excitotoxicity in neurodegenerative disease and some mood
dysregulation, but elevated—not deficient—glutamate is the concern. Option E
(acetylcholine deficiency) is relevant to cognitive disorders, not depression.
QUESTION 2: Psychopharmacology - SSRIs
A 38-year-old woman with generalized anxiety disorder is prescribed
sertraline 50 mg daily. She reports nausea, restlessness, and insomnia
beginning 3 days after initiation. Which intervention is most appropriate at
this time?
A) Discontinue sertraline immediately and switch to a tricyclic antidepressant
B) Reassure the patient that these symptoms typically resolve within 1–2 weeks and
continue the current dose
C) Increase the dose to 100 mg to achieve therapeutic levels faster
D) Add benzodiazepine monotherapy and taper sertraline over 1 week
E) Switch to fluoxetine, which has fewer initial adverse effects
, CORRECT ANSWER: B) Reassure the patient that these symptoms typically
resolve within 1–2 weeks and continue the current dose
RATIONALE: Initial SSRI side effects (nausea, agitation, insomnia) are common and
predictable, occurring in 20–30% of patients in the first week. These are dose-
independent and typically resolve within 7–14 days as the brain adapts. Early
discontinuation or dose escalation often perpetuates the cycle of side effects.
Standard practice is to reassure, counsel the patient on timing expectations,
consider timing adjustment (e.g., taking sertraline in the morning to mitigate
insomnia), and allow time for tolerance. Option A (discontinuation) is premature
and abandons an evidence-based first-line agent. Option C (escalation) worsens
tolerability. Option D (benzodiazepine monotherapy) is inappropriate monotherapy
and adds dependence risk. Option E (fluoxetine switch) is unnecessary; the side-
effect profile is similar across SSRIs, and switching provides no advantage at this
stage.
QUESTION 3: Diagnostic Assessment - Bipolar I Disorder
A 29-year-old male is brought to the clinic by his wife after a 5-day period of
decreased need for sleep (3 hours/night), pressured speech, racing thoughts,
and impulsive spending of $8,000. He has no prior psychiatric history. Which
diagnosis best fits this clinical presentation?
A) Attention-deficit/hyperactivity disorder with impulsivity
B) Major depressive disorder with agitation
C) Bipolar I disorder, current manic episode
D) Substance-induced mood disorder
E) Generalized anxiety disorder with restlessness
CORRECT ANSWER: C) Bipolar I disorder, current manic episode
RATIONALE: The presentation meets DSM-5 criteria for a manic episode: a distinct
period of abnormally and persistently elevated/expansive mood lasting ≥3 days
(here, 5 days), plus ≥3 of the DIGFAST criteria (Distractibility, Impulsivity,
, Grandiosity/goal-directedness, Flight of ideas, Activity increase, Sleep decrease,
Talkativeness). This patient exhibits flight of ideas, decreased sleep need, goal-
directed activity (spending), pressured speech, and impulsivity—classic manic
features. First manic episode with no prior major depressive episodes = Bipolar I
Disorder. Option A (ADHD) does not account for the acute mood elevation and
dramatic behavioral shift. Option B (major depression with agitation) lacks
depressed mood and misinterprets the presentation. Option D (substance-induced)
requires substance use history; none is provided. Option E (GAD) does not explain
the decreased sleep need or goal-directed activity characteristic of mania.
QUESTION 4: Psychopharmacology - Mood Stabilizers
A 34-year-old female with Bipolar I Disorder has been stable on lithium 900
mg daily (level 0.8 mEq/L) for 18 months. She presents with tremor, polyuria,
and polydipsia. Which complication is most concerning in this scenario?
A) Acute lithium toxicity requiring immediate dialysis
B) Nephrogenic diabetes insipidus as a chronic lithium side effect
C) Hypothyroidism secondary to chronic lithium use
D) Nephrotic syndrome from glomerulonephritis
E) Metabolic acidosis from lithium accumulation
CORRECT ANSWER: B) Nephrogenic diabetes insipidus as a chronic lithium
side effect
RATIONALE: Polyuria and polydipsia in a patient on chronic lithium therapy
strongly suggest nephrogenic diabetes insipidus (NDI), a dose-dependent but often
irreversible side effect affecting the collecting duct's response to antidiuretic
hormone. Tremor is an expected dose-related effect of lithium. The lithium level
(0.8 mEq/L) is within the therapeutic range (0.6–1.2 mEq/L), making acute toxicity
unlikely. NDI occurs in 20–40% of patients on long-term lithium and manifests as
polyuria, polydipsia, and inability to concentrate urine. While hypothyroidism is a
common lithium side effect (occurring in ~30% of patients), it does not explain the
acute polyuria and polydipsia. Option A (acute toxicity) is inconsistent with a
